CORDIS
EU research results

CORDIS

English EN
Female cancer prediction using cervical omics to individualise screening and prevention

Female cancer prediction using cervical omics to individualise screening and prevention

Objective

While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 3 634 565,11

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 718 182,50

UNIVERZITA KARLOVA

Czechia

EU Contribution

€ 426 520

HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL

Norway

EU Contribution

€ 269 697,50

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Italy

EU Contribution

€ 236 500

UNIVERSITY HOSPITALS SOUTHAMPTON NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 78 926,50

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 311 700

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 350 077,50

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 578 500

ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH

Austria

EU Contribution

€ 498 440

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 248 987,50

EURAM LIMITED

United Kingdom

EU Contribution

€ 83 679,64

Eurofins Genomics Europe Sequencing GmbH

Germany

EU Contribution

€ 558 970

Project information

Grant agreement ID: 634570

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 7 994 746,25

  • EU contribution

    € 7 994 746,25

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom